Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial

Area of Science:

• Neurology
• Medical Devices
• Clinical Trials

Background:

• Migraine affects 12% of the global population, causing significant disability.
• Current preventive treatments have limitations, including inadequate efficacy and adverse events, necessitating novel therapeutic options.
• Caloric vestibular stimulation (CVS) presents a potential adjunctive therapy for migraine prevention.

Purpose of the Study:

• To assess the safety and efficacy of a new solid-state caloric vestibular stimulation (CVS) device.
• To evaluate the device as an adjuvant therapy for preventing episodic migraine in adults.

Main Methods:

• A multicenter, randomized, placebo-controlled trial involving adult migraineurs.
• Three months of treatment with the TNM™ device for CVS.
• Primary endpoint: change in monthly migraine days; secondary endpoints: responder rates, analgesic use, pain scores, and safety assessments.

Main Results:

• Active treatment group showed a significant reduction in monthly migraine days (-3.9 days) compared to placebo (-1.1 days).
• Greater improvements observed in acute medication usage and pain scores in the active group.
• The device was well-tolerated, with no adverse effects on mood, cognition, or balance, and high treatment adherence (90%).

Conclusions:

• The TNM™ device for CVS demonstrates clinical efficacy and high tolerability.
• It represents a promising adjuvant therapy for the prevention of episodic migraine.
• The study supports CVS as a safe and effective non-pharmacological migraine management strategy.